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Abstract
Background: Umbilical metastases from a malignant neoplasm, also termed Sister Mary Joseph's
nodule, are not commonly reported in the English literature, and they have usually been considered
as a sign of a poor prognosis for the patient. The present article reports on the current view point
on umbilical metastasis besides discussing the epidemiology, clinical presentation, pathophysiology
and treatment.
Method: A search of Pubmed was carried out using the term 'umblic*' and 'metastases' or
metastasis' revealed no references. Another search was made using the term "Sister Joseph's
nodule" or sister Joseph nodule" that revealed 99 references. Of these there were 14 review
articles, however when the search was limited to English language it yielded only 20 articles.
Articles selected from these form the basis of this report along with cross references.
Results: The primary lesions usually arise from gastrointestinal or genitourinary tract malignancies
and may be the presenting symptom or sign of a primary tumour in an unknown site.
Conclusion: A careful evaluation of all umbilical lesions, including an early biopsy if appropriate, is
recommended. Recent studies suggest an aggressive surgical approach combined with
chemotherapy for such patients may improve survival.
Background
Cutaneous metastases localised to the umbilicus are
named "Sister Mary Joseph's nodules". In 1949 Sir Ham-
ilton Bailey initially used this eponym in his book "Phys-
ical Signs in Clinical Surgery" to describe umbilical
metastases, in honour of Sister Mary Joseph, the superin-
tendent nurse and surgical assistant of Dr. William Mayo
at St. Mary's Hospital in Rochester (presently the Mayo
Clinic in Minnesota, USA). Sister Mary Joseph was the first
to note the link between umbilical nodules and intra
abdominal malignancy [1-4].
Epidemiology
The occurrence of cutaneous metastases from malignant
neoplasms occurs in from 1% to up to 9% of individuals,
as determined at autopsy. Those metastases to the umbili-
cus are uncommon and represent only 10% of all second-
ary tumours which have spread to the skin [5,6].
Epidemiological studies showed that this condition pre-
dominates in females [7].
From a review of the literature, umbilical neoplastic nod-
ules can be due to a primary tumour in 38% of cases, due
to endometriosis in 32% of individuals, and in 30% are
actually secondary tumour deposits from a primary
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tumour deposits then the source of the primary tumour
may be from the gastrointestinal (35–65%) and geni-
tourinary (12–35%) tract. In addition, in 3–6% of cases it
originates from haematological malignancies, or lung and
breast cancers. In 15% to 30% of patients the source of the
primary site of the tumour remains unknown [9-11].
Clinical findings
Sister Mary Joseph's nodules usually present as a painful
lump on the anterior abdominal wall. It has irregular mar-
gins and a hard fibrous consistency. The surface may be
ulcerated and necrotic, with either blood, serous, puru-
lent, or mucous discharge from it. The size of the nodule
usually ranges from 0.5 to 2 cm, although some nodules
may reach up to 10 cm in size [8]. High-resolution ultra-
sound (US) helps to clarify the clinical findings by detect-
ing solid umbilical nodules, even if the diagnosis is
difficult to make clinically. Moreover, careful examination
and imaging of the abdominal contents may also point to
the diagnosis [12].
Pathophysiology
A full understanding of the mechanisms whereby the
tumour spreads to the umbilicus remains unclear. How-
ever, following anatomical criteria, and several hypothesis
have been proposed.
The umbilical ring is a scar invaginated on the abdominal
wall between the transversalis fascia and peritoneum.
After birth, the foetal cord structures develop into liga-
ments or peritoneal folds: 1) median umbilical ligament
secondary to the obliterating urachus, 2) medial umbilical
ligaments (which are obliterated umbilical arteries); 3)
ligamentum teres (obliterated left umbilical vein) that
continues into 4) the falciform ligament. On the lateral
umbilical folds the inferior epigastric vessels and, some-
times, a vestigial vitelline duct connecting the umbilicus
to the ileum can be recognised. The umbilical region
shows a rich arterial supply that includes the inferior epi-
gastric and deep circumflex iliac branches of the external
iliac artery, and the superior epigastric branch of the inter-
nal mammary artery.
The venous drainage includes several anastomotic
branches, coming from cranially the axillary vein, through
the internal mammary vein, and caudally, the femoral
vein through the superficial epigastric vein. In addition,
the umbilicus may be connected with the portal system,
through small umbilical veins.
The lymphatic system connects the umbilical region to the
axillary, inguinal, and para-aortic lymph nodes. The deep
lymphatic system passes along the falciform ligament,
pierces the diaphragm and enters the anterior mediasti-
num or courses to the nodes around the iliac arteries [12-
15].
All these systems (arterial, venous and lymphatic) as
described represent possible routes by which metastatic
tumour cells could implant into the umbilical region.
It is reasonable to suggest that direct extension of tumour
through the peritoneum is the preferred route for gas-
trointestinal tumours. Furthermore, the common associa-
tion between hepatic and umbilical metastases might
suggests that the hypothesis that the tumour spreads from
the primary tumour to the liver through the portal system
and then through the lymphatic and/or venous channels,
they spread to the umbilicus. It is still unclear if the umbil-
ical tumour spread precedes the hepatic spread or vice
versa.
Renal cell carcinoma typically spreads via extra-renal
extension, lymphatic dissemination or venous invasion
by the tumour. Intraperitoneal spread may occur as a
result of disruption of the renal capsule [16]. The dissem-
ination of neoplastic cell through the urachus is assumed
to be the mechanism for the bladder cancers.
Haematogenous, lymphatic and venous spread all repre-
sent valid mechanisms of tumour spread from gynaeco-
logical cancers [7,14].
Prognosis and therapy
Usually the presence of an umbilical metastasis indicates
a poor prognosis, is a sign of advanced neoplastic disease,
and may not be amenable to surgery. The survival of these
patients without treatment has been reported to range
from 2 to 11 months from the time of initial diagnosis
[17-19].
However, recent studies have suggested that there are sev-
eral factors which are able to influence the prognosis of
such patients. Certain data has shown a better survival
(mean 9.7 months) in patients who detect an umbilical
metastasis before definitive treatment of the primary
tumour. In contrast, when the lesion appears after the pri-
mary tumour has been treated then the survival for these
patients does not exceed the 7.6 months [16,17].
Moreover, the aetiology of the primary malignancy deter-
mines the prognosis. For example, a better survival rate for
patients with primary ovarian carcinoma has been
reported previously [14].
Finally, the type of treatment seems able to influence the
patient's prognosis. Despite some authors proposing only
palliative treatment because of these patients poor prog-
nosis [10,17,20], recent studies have demonstrated thatPage 2 of 3
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there is a better survival (21 months) for patients if they
are treated with a combination of surgery and adjuvant
therapy instead of surgery alone (7.4 months) or chemo-
therapy alone (10.3 months) [9,11,14,18].
Obviously, the appropriateness of such an aggressive
treatment approach is determined by the clinical state of
the patient.
Conclusion
A careful examination of all umbilical lesions is recom-
mended, especially in those patients with gastrointestinal
and genitourinary tract malignancies. All umbilical mass
lesions should be biopsied to determinate the pathologi-
cal nature of the lesion.
Clinical experience suggests that, whenever it is possible,
an aggressive surgical approach combined with chemo-
therapy treatment may be considered to offer the patient
the best survival probability.
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